Juanita A. Draime
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juanita A. Draime has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Aleda M. H. Chen
College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
6 shared publications - Eliya Craig
School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA
4 shared publications - Nathan Gibson
School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA
4 shared publications - Kyrie Eleyson R. Baden
School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA
3 shared publications Aleda M.H. Chen
Cedarville University School of Pharmacy Cedarville OH USA
2 shared publicationsDouglas C. Anderson
2 shared publications
Latest Publications
- Open Access
Utilization of Provider–Patient Communication Tools and Approaches to Facilitate Vaccine Confidence: A Systematic Review
Background/Objectives: With declining vaccine coverage and rising concerns regarding vaccines, vaccine-preventable diseases are rising. Many research studies have examined approaches to enhance the acceptance of vaccines, but the integration of these approaches into practice has been limited. Thus, the objective was to identify recent evidence surrounding provider–patient communication tools and approaches related to vaccination confidence. Methods: A systematic review following PRISMA methodology was conducted. Using a pre-specified search strategy aligned with the research objective and performed in PubMed, CINAHL, and Web of Science, articles were evaluated by two researchers independently, with a third resolving discrepancies, at the title and abstract screening, full-text review, quality assessment, and data extraction phases. Extraction data were descriptively analyzed, including the impact on vaccine acceptance, and synthesized thematically. Results: From the 2291 studies which underwent screening, a total of, 143 articles were included. Most studies were conducted in the United States, in the outpatient setting, and utilized physicians and nurses to deliver the intervention. Many vaccines were covered, with the greatest number of studies focusing on influenza, HPV, and pneumococcal vaccines. The three predominant communication approaches and tools utilized were provider-focused training, direct patient education/materials, and provider–patient communication strategies. These strategies often focused on addressing knowledge gaps, health beliefs, and common concerns. Over two-thirds of studies increased vaccine acceptance following communication interventions. Conclusions: To address vaccine concerns, it is important to ensure providers have the education and training necessary as well as tools to address underlying causes of concerns. When equipped, providers are able to improve vaccine acceptance.
Open AccessUtilization of Provider–Patient Communication Tools and Approaches to Facilitate Vaccine Confidence: A Systematic Review
Background/Objectives: With declining vaccine coverage and rising concerns regarding vaccines, vaccine-preventable diseases are rising. Many research studies have examined approaches to enhance the acceptance of vaccines, but the integration of these approaches into practice has been limited. Thus, the objective was to identify recent evidence surrounding provider–patient communication tools and approaches related to vaccination confidence. Methods: A systematic review following PRISMA methodology was conducted. Using a pre-specified search strategy aligned with the research objective and performed in PubMed, CINAHL, and Web of Science, articles were evaluated by two researchers independently, with a third resolving discrepancies, at the title and abstract screening, full-text review, quality assessment, and data extraction phases. Extraction data were descriptively analyzed, including the impact on vaccine acceptance, and synthesized thematically. Results: From the 2291 studies which underwent screening, a total of, 143 articles were included. Most studies were conducted in the United States, in the outpatient setting, and utilized physicians and nurses to deliver the intervention. Many vaccines were covered, with the greatest number of studies focusing on influenza, HPV, and pneumococcal vaccines. The three predominant communication approaches and tools utilized were provider-focused training, direct patient education/materials, and provider–patient communication strategies. These strategies often focused on addressing knowledge gaps, health beliefs, and common concerns. Over two-thirds of studies increased vaccine acceptance following communication interventions. Conclusions: To address vaccine concerns, it is important to ensure providers have the education and training necessary as well as tools to address underlying causes of concerns. When equipped, providers are able to improve vaccine acceptance.
- Open Access
The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review
Background/Objectives: Glucosamine and chondroitin are natural substances often used alone or in combination for conditions affecting the joints. Our objective was to evaluate the efficacy and safety of glucosamine and/or chondroitin supplementation in humans as well as to determine the common dosages used. Methods: A systematic review was conducted using PRISMA methodology. Searches were performed in PubMed and Web of Science and uploaded into Covidence where two independent researchers reviewed articles according to inclusion and exclusion criteria. Quality assessment was performed using the Mixed Methods Appraisal Tool (MMAT). Results: Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S. Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects. Glucosamine and chondroitin were most commonly administered together at daily doses of 1500 mg and 1200 mg, respectively, and often compared to a placebo or celecoxib. Conclusions: Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.
Open AccessThe Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review
Background/Objectives: Glucosamine and chondroitin are natural substances often used alone or in combination for conditions affecting the joints. Our objective was to evaluate the efficacy and safety of glucosamine and/or chondroitin supplementation in humans as well as to determine the common dosages used. Methods: A systematic review was conducted using PRISMA methodology. Searches were performed in PubMed and Web of Science and uploaded into Covidence where two independent researchers reviewed articles according to inclusion and exclusion criteria. Quality assessment was performed using the Mixed Methods Appraisal Tool (MMAT). Results: Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S. Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects. Glucosamine and chondroitin were most commonly administered together at daily doses of 1500 mg and 1200 mg, respectively, and often compared to a placebo or celecoxib. Conclusions: Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.
- Open Access
- 17 March 2025
- Published by Elsevier in JAPhA Practice Innovations
- Vol. 2 (3)
Impact of pharmacist-led continuous glucose monitoring program on reduction in A1c in an FQHC
- 17 March 2025
- Published by Elsevier in JAPhA Practice Innovations
- Vol. 2 (3)
Open AccessImpact of pharmacist-led continuous glucose monitoring program on reduction in A1c in an FQHC
- Open Access
S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound implicated in the treatment of liver dysfunction. In this systematic review, our objective was to determine the efficacy, safety, and optimal dose of SAMe in liver diseases. Methods: Using the PRISMA methodology, we searched PubMed, CINAHL, and Web of Science using key MeSH search terms. For title/abstract screening, full-text review, and data extraction, two independent researchers reviewed articles, and a third researcher resolved conflicts. Data extraction also included a quality assessment of included articles. Results: Of the 1881 non-duplicated studies, 15 articles focusing on SAMe use in the liver were included. All included studies (n = 15) scored a 4 or 5 out of 5 points on the quality assessment, which indicated high study quality. Overall, SAMe was effective in improving liver-related parameters with few adverse events, which were primarily mild, transient gastrointestinal complaints. Conclusions: The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement. Future studies are needed to assess long-term efficacy and safety data of SAMe and the optimal route of administration in liver diseases.
Open AccessS-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound implicated in the treatment of liver dysfunction. In this systematic review, our objective was to determine the efficacy, safety, and optimal dose of SAMe in liver diseases. Methods: Using the PRISMA methodology, we searched PubMed, CINAHL, and Web of Science using key MeSH search terms. For title/abstract screening, full-text review, and data extraction, two independent researchers reviewed articles, and a third researcher resolved conflicts. Data extraction also included a quality assessment of included articles. Results: Of the 1881 non-duplicated studies, 15 articles focusing on SAMe use in the liver were included. All included studies (n = 15) scored a 4 or 5 out of 5 points on the quality assessment, which indicated high study quality. Overall, SAMe was effective in improving liver-related parameters with few adverse events, which were primarily mild, transient gastrointestinal complaints. Conclusions: The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement. Future studies are needed to assess long-term efficacy and safety data of SAMe and the optimal route of administration in liver diseases.
- Open Access
S-Adenosylmethionine (SAMe) for Central Nervous System Health: A Systematic Review
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound used to improve mood-related symptoms. Our aim was to determine the efficacy, safety, and optimal dose of SAMe in Central Nervous System (CNS) signs (e.g., mood, behavior). Methods: We conducted a PRISMA-based systematic review by searching PubMed, CINAHL, and Web of Science using MeSH search terms. Articles were independently reviewed by two researchers (with a third resolving conflicts) during title/abstract screening and full-text review. Data were extracted in the same approach, with a quality assessment of included articles. Results: Out of 1881 non-duplicated studies, 36 were included in the review focusing on CNS signs (mood, behavior, sleep). Most studies (n = 32) achieved a 4 or 5 out of 5 points, indicating high study quality. Overall, SAMe was effective in 24 of 36 studies, with adverse events mostly consisting of mild, transient gastrointestinal disturbances. Conclusions: Many patients in these studies did experience improvements in CNS signs from using SAMe alone or in combination with existing therapy. However, future studies are needed to further understand the long-term effects of SAMe in the CNS.
Open AccessS-Adenosylmethionine (SAMe) for Central Nervous System Health: A Systematic Review
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound used to improve mood-related symptoms. Our aim was to determine the efficacy, safety, and optimal dose of SAMe in Central Nervous System (CNS) signs (e.g., mood, behavior). Methods: We conducted a PRISMA-based systematic review by searching PubMed, CINAHL, and Web of Science using MeSH search terms. Articles were independently reviewed by two researchers (with a third resolving conflicts) during title/abstract screening and full-text review. Data were extracted in the same approach, with a quality assessment of included articles. Results: Out of 1881 non-duplicated studies, 36 were included in the review focusing on CNS signs (mood, behavior, sleep). Most studies (n = 32) achieved a 4 or 5 out of 5 points, indicating high study quality. Overall, SAMe was effective in 24 of 36 studies, with adverse events mostly consisting of mild, transient gastrointestinal disturbances. Conclusions: Many patients in these studies did experience improvements in CNS signs from using SAMe alone or in combination with existing therapy. However, future studies are needed to further understand the long-term effects of SAMe in the CNS.
- 11 November 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 402-407
Descriptive analysis of the legal ramifications of medication diversion by pharmacy employees
- 11 November 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 402-407
Descriptive analysis of the legal ramifications of medication diversion by pharmacy employees
- 24 December 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (4) , S101-S105
Implementation of a pharmacist-led spirometry clinic
- 24 December 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (4) , S101-S105
Implementation of a pharmacist-led spirometry clinic
- Open Access
- 18 March 2022
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 5, 100129
Food as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes
- 18 March 2022
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 5, 100129
Open AccessFood as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes
- 1 August 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (8) , 1040-1045
Implementation and assessment patient cases using the SBAR method to teach patient quality of life issues
- 1 August 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (8) , 1040-1045
Implementation and assessment patient cases using the SBAR method to teach patient quality of life issues
- 1 October 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (10) , 1245-1251
Training student pharmacists to facilitate human immunodeficiency virus point-of-care testing
- 1 October 2020
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 12 (10) , 1245-1251
Training student pharmacists to facilitate human immunodeficiency virus point-of-care testing